S01E26: TETON-2 and IPF — Does Inhaled Treprostinil Change Practice?

In this episode of PRISM Rounds, we break down the March 2026 New England Journal of Medicine trial Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. We review what the trial showed, what it did not prove, how to interpret the FVC signal, the clinical-worsening endpoint, tolerability, and what this means for intensivists, pulmonologists, fellows, residents, and ILD clinicians.We also place the study in context with the earlier INCREASE trial in pulmonary hypertension due to interstitial lung disease. This episode is built for busy clinicians who want practical bedside translation, key teaching points, and concise evidence-based discussion with light professional banter.Full article linksTETON-2 PubMed: https://pubmed.ncbi.nlm.nih.gov/41812190/TETON-2 NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2512911INCREASE PubMed: https://pubmed.ncbi.nlm.nih.gov/33440084/INCREASE NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2008470Tags#CriticalCare #ICU #Pulmonary #PulmCrit #SleepMedicine #InternalMedicine #Pulmonology #RespiratoryMedicine #IntensiveCare #MedicalEducation #MedEd #FOAMed #FOAMcc #MedTwitter #JournalClub #EvidenceBasedMedicine #MedicalPodcast #PodcastMedicine #IPF #IdiopathicPulmonaryFibrosis #ILD #InterstitialLungDisease #PulmonaryFibrosis #PulmonaryHypertension #PHILD #Treprostinil #InhaledTreprostinil #NEJM #LungDisease #CriticalCareMedicine #AcademicMedicine #BoardReview #Fellowship #Residency #TeachingRounds #ClinicianEducation #RespiratoryFailure #PulmonaryResearch